Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging role of long non-coding RNAs in cisplatin resistance
Yang Hu, Qiong-Ni Zhu, Jun‐Li Deng, et al.
OncoTargets and Therapy (2018) Vol. Volume 11, pp. 3185-3194
Open Access | Times Cited: 72

Showing 1-25 of 72 citing articles:

LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms
Э. А. Брага, М. В. Фридман, Alexey A. Moscovtsev, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 22, pp. 8855-8855
Open Access | Times Cited: 194
Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms
Fei Li, Zaosong Zheng, Wei Chen, et al.
Drug Resistance Updates (2023) Vol. 68, pp. 100938-100938
Closed Access | Times Cited: 98
LncRNA NEAT1 promotes docetaxel resistance in prostate cancer by regulating ACSL4 via sponging miR-34a-5p and miR-204-5p
Xingkang Jiang, Shanqi Guo, Yangyi Zhang, et al.
Cellular Signalling (2019) Vol. 65, pp. 109422-109422
Closed Access | Times Cited: 118
Phytochemicals: Current strategy to sensitize cancer cells to cisplatin
Chao‐Yue Sun, Qian-Yu Zhang, Guangjuan Zheng, et al.
Biomedicine & Pharmacotherapy (2018) Vol. 110, pp. 518-527
Open Access | Times Cited: 110
The nuclear hypoxia-regulated NLUCAT1 long non-coding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress
Laura Moreno Leon, Marine Gautier‐Isola, Richard Allan, et al.
Oncogene (2019) Vol. 38, Iss. 46, pp. 7146-7165
Closed Access | Times Cited: 89
Curcumin–cisplatin chemotherapy: A novel strategy in promoting chemotherapy efficacy and reducing side effects
Yaseen Hussain, Lubna Islam, Haroon Khan, et al.
Phytotherapy Research (2021) Vol. 35, Iss. 12, pp. 6514-6529
Closed Access | Times Cited: 76
Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability
Giasemi C. Eptaminitaki, Dimitris Stellas, Benjamin Bonavida, et al.
Drug Resistance Updates (2022) Vol. 65, pp. 100866-100866
Closed Access | Times Cited: 51
Moving beyond cisplatin resistance: mechanisms, challenges, and prospects for overcoming recurrence in clinical cancer therapy
Rui Fu, Borui Zhao, Min Chen, et al.
Medical Oncology (2023) Vol. 41, Iss. 1
Closed Access | Times Cited: 24
The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis
Liangfeng Chen, Xiaobing Han, Zhongzhou Hu, et al.
Cancer Chemotherapy and Pharmacology (2019) Vol. 83, Iss. 5, pp. 921-931
Closed Access | Times Cited: 75
Targeting STAT3 inhibition to reverse cisplatin resistance
Chao‐Yue Sun, Juan Nie, Jie-Peng Huang, et al.
Biomedicine & Pharmacotherapy (2019) Vol. 117, pp. 109135-109135
Open Access | Times Cited: 72
The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation
Hao Wang, Lei Fang, Jing Jiang, et al.
Cell Death and Disease (2018) Vol. 9, Iss. 11
Open Access | Times Cited: 71
lncRNA CCAT1 is a biomarker for the proliferation and drug resistance of esophageal cancer via the miR‐143/PLK1/BUBR1 axis
Min Hu, Qi Zhang, Xiao‐Hui Tian, et al.
Molecular Carcinogenesis (2019) Vol. 58, Iss. 12, pp. 2207-2217
Closed Access | Times Cited: 69
Exosomal noncoding RNAs: key players in glioblastoma drug resistance
Ahmad Movahedpour, Seyyed Hossein Khatami, Marjan Khorsand, et al.
Molecular and Cellular Biochemistry (2021) Vol. 476, Iss. 11, pp. 4081-4092
Closed Access | Times Cited: 46
lncRNA lnc-POP1-1 upregulated by VN1R5 promotes cisplatin resistance in head and neck squamous cell carcinoma through interaction with MCM5
Yingying Jiang, Haiyan Guo, Tong Tong, et al.
Molecular Therapy (2021) Vol. 30, Iss. 1, pp. 448-467
Open Access | Times Cited: 44
LncRNA-MALAT1 mediates cisplatin resistance via miR-101-3p/VEGF-C pathway in bladder cancer
Peihua Liu, Xiaozhou Li, Yu Cui, et al.
Acta Biochimica et Biophysica Sinica (2019) Vol. 51, Iss. 11, pp. 1148-1157
Open Access | Times Cited: 53
RETRACTED ARTICLE: Long non-coding RNA TPTEP1 inhibits hepatocellular carcinoma progression by suppressing STAT3 phosphorylation
Hongda Ding, Junpeng Liu, Ruoyao Zou, et al.
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 52
Recent Progress in Characterizing Long Noncoding RNAs in Cancer Drug Resistance
Wenyuan Zhao, Bin Shan, Dan He, et al.
Journal of Cancer (2019) Vol. 10, Iss. 26, pp. 6693-6702
Open Access | Times Cited: 48
<p>NEAT1 Knockdown Suppresses the Cisplatin Resistance in Ovarian Cancer by Regulating miR-770-5p/PARP1 Axis</p>
Mingzhe Zhu, Lei Yang, Xin Wang
Cancer Management and Research (2020) Vol. Volume 12, pp. 7277-7289
Open Access | Times Cited: 46
Multiple Roles of Exosomal Long Noncoding RNAs in Cancers
Wenyuan Zhao, Yuanqi Liu, Chunfang Zhang, et al.
BioMed Research International (2019) Vol. 2019, pp. 1-12
Open Access | Times Cited: 44
Long Non-coding RNAs Involved in Resistance to Chemotherapy in Ovarian Cancer
Cecilie Abildgaard, Luísa Matos do Canto, Karina Dahl Steffensen, et al.
Frontiers in Oncology (2020) Vol. 9
Open Access | Times Cited: 44
Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling
Wenxi Tan, Ge Sun, Mengyuan Shangguan, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 40
Competing endogenous RNAs in lung cancer
Meilian Zhao, Jianguo Feng, Liling Tang
Cancer Biology and Medicine (2021) Vol. 18, Iss. 1, pp. 1-20
Open Access | Times Cited: 34
A state-of-art of underlying molecular mechanisms and pharmacological interventions/nanotherapeutics for cisplatin resistance in gastric cancer
Jitendra Gupta, Abdulrahman T. Ahmed, Nahla A. Tayyib, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 166, pp. 115337-115337
Open Access | Times Cited: 15
MicroRNAs as the critical regulators of autophagy-mediated cisplatin response in tumor cells
Faezeh Tolue Ghasaban, Amirhosein Maharati, Iman Akhlaghipour, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 14
The functional role of long noncoding RNA in resistance to anticancer treatment
Yidi Qu, Hor‐Yue Tan, Yau-Tuen Chan, et al.
Therapeutic Advances in Medical Oncology (2020) Vol. 12
Open Access | Times Cited: 39
Page 1 - Next Page

Scroll to top